Evidence map›Paper›PMID 24940052›Full record

Trial reportClinical interventions in aging2014

Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study.

Zbigniew Pietrzkowski, Michael J Phelan, Robert Keller, Cynthia Shu, Ruby Argumedo, Tania Reyes-Izquierdo

Erratum issued Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical interventions in aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05438979 (Auburn University Joint Health Study), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05438979 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Auburn University Joint Health Study

TypeinterventionalSponsorAuburn UniversityRan2022 to 2024Enrolled300ConditionsEffect of DrugArmsPlacebo, Calcium Fructoborate
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Calcium Fructoborate for Bone and Cardiovascular Health.Biological trace element research · 2016
    Article
  9. Nothing Boring About Boron.Integrative medicine (Encinitas, Calif.) · 2015
    Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zbigniew PietrzkowskiFutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
Michael J PhelanDepartment of Statistics, School of Information and Computer Science, University of California at Irvine, CA, USA.
Robert KellerNutraClinical Inc., Irvine, CA, USA.
Cynthia ShuFutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
Ruby ArgumedoFutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
Tania Reyes-IzquierdoFutureCeuticals, Inc., Applied BioClinical Laboratory, University of California at Irvine, CA, USA.
BioClinica (United States) · USUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcium fructoborate (CFB) at a dose of 110 mg twice per day was previously reported to improve knee discomfort during the first 14 days of treatment. In this study, 60 participants with self-reported knee discomfort were randomized into two groups receiving CFB or placebo. Initial levels of knee discomfort were evaluated by Western Ontario and McMaster Universities Arthritis Index (WOMAC) and McGill Pain Questionnaire (MPQ) scores at the beginning of the study and also at 7 and 14 days after treatment. Results showed that supplementation with CFB significantly improved knee discomfort in the study subjects; significant reductions of mean within-subject change in WOMAC and MPQ scores were observed for the CFB group compared to the placebo group at both 7 and 14 days after treatment. Estimated treatment differences for the MPQ score were -5.8 (P=0.0009) and -8.9 (P<0.0001) at Day 7 and 14, respectively. Estimated differences for the WOMAC score were -5.3 (P=0.06) and -13.73 (P<0.0001) at Day 7 and 14, respectively. Negative values indicate greater reductions in reported discomfort. On both Day 7 and Day 14, the trend was toward greater improvement in the CFB group. The placebo group did not exhibit any change in the WOMAC and MPQ scores. In conclusion, supplementation with 110 mg CFB twice per day was associated with improving knee discomfort during the 2 weeks of intake.

Indexed as

AdultAnti-Inflammatory AgentsArthralgiaBoratesDouble-Blind MethodFemaleFructoseHumansKnee JointMaleMiddle AgedOsteoarthritis, KneePain MeasurementSurveys and QuestionnairesAnti-Inflammatory AgentsBoratescalcium fructoborateFructoseCFBjoint discomfortMcGill pain scoreWOMAC score

Identifiers

PMID24940052
PMCPMC4051624
OpenAlexW2009645511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.